CDSCO Panel Accepts Glenmark's Apremilast Trial Report, Seeks 2-Year PSUR Data
Glenmark
New Delhi: Glenmark Pharmaceuticals Limited has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), for its Phase-IV clinical trial study report on Apremilast 10/20/30 mg tablets for the treatment of active psoriatic arthritis, subject to submission of ongoing post-marketing safety data.
The matter was discussed at the 7th meeting of the SEC held on 23rd July 2025 at CDSCO headquarters, New Delhi. Referring to its earlier recommendation dated 14th March 2024, the committee reviewed Glenmark’s summary report, which included data from 169 patients, along with justification for closure of the study, real-world clinical data, and Periodic Safety Update Reports (PSURs).
Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor approved for treating moderate to severe plaque psoriasis and active psoriatic arthritis. It has gained traction in India due to supportive global and Indian studies demonstrating long-term safety and efficacy in autoimmune dermatological conditions.
After reviewing the clinical trial outcomes and safety profile, the expert panel found the data relevant for therapeutic application in the Indian population.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.